159 related articles for article (PubMed ID: 17115723)
1. Adventures in drug discovery: potent agents based on ligands for cell-surface receptors.
Maryanoff BE
Acc Chem Res; 2006 Nov; 39(11):831-40. PubMed ID: 17115723
[TBL] [Abstract][Full Text] [Related]
2. Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.
Xiang MA; Rybczynski PJ; Patel M; Chen RH; McComsey DF; Zhang HC; Gunnet JW; Look R; Wang Y; Minor LK; Zhong HM; Villani FJ; Demarest KT; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 Dec; 17(23):6623-8. PubMed ID: 17942308
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.
Guillon G; Derick S; Pena A; Cheng LL; Stoev S; Seyer R; Morgat JL; Barberis C; Gal CS; Wagnon J; Manning M
J Neuroendocrinol; 2004 Apr; 16(4):356-61. PubMed ID: 15089974
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
[TBL] [Abstract][Full Text] [Related]
6. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
7. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
[TBL] [Abstract][Full Text] [Related]
9. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges.
Chini B; Manning M
Biochem Soc Trans; 2007 Aug; 35(Pt 4):737-41. PubMed ID: 17635137
[TBL] [Abstract][Full Text] [Related]
10. Drugs and their molecular targets: an updated overview.
Landry Y; Gies JP
Fundam Clin Pharmacol; 2008 Feb; 22(1):1-18. PubMed ID: 18251718
[TBL] [Abstract][Full Text] [Related]
11. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.
Chini B; Manning M; Guillon G
Prog Brain Res; 2008; 170():513-7. PubMed ID: 18655904
[TBL] [Abstract][Full Text] [Related]
12. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
Ali F; Raufi MA; Washington B; Ghali JK
Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Patel M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2987-9. PubMed ID: 15125974
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and selective small-molecule PAR-2 agonists.
Seitzberg JG; Knapp AE; Lund BW; Mandrup Bertozzi S; Currier EA; Ma JN; Sherbukhin V; Burstein ES; Olsson R
J Med Chem; 2008 Sep; 51(18):5490-3. PubMed ID: 18720984
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
Low PS; Henne WA; Doorneweerd DD
Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
[TBL] [Abstract][Full Text] [Related]
17. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo.
Conn PM; Ulloa-Aguirre A; Ito J; Janovick JA
Pharmacol Rev; 2007 Sep; 59(3):225-50. PubMed ID: 17878512
[TBL] [Abstract][Full Text] [Related]
18. New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.
Yea CM; Allan CE; Ashworth DM; Barnett J; Baxter AJ; Broadbridge JD; Franklin RJ; Hampton SL; Hudson P; Horton JA; Jenkins PD; Penson AM; Pitt GR; Rivière P; Robson PA; Rooker DP; Semple G; Sheppard A; Haigh RM; Roe MB
J Med Chem; 2008 Dec; 51(24):8124-34. PubMed ID: 19053774
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal steroid receptor modulators.
Hermkens PH; Kamp S; Lusher S; Veeneman GH
IDrugs; 2006 Jul; 9(7):488-94. PubMed ID: 16821162
[TBL] [Abstract][Full Text] [Related]
20. Screening the receptorome: an efficient approach for drug discovery and target validation.
Strachan RT; Ferrara G; Roth BL
Drug Discov Today; 2006 Aug; 11(15-16):708-16. PubMed ID: 16846798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
